CurrentEndo — Endocrine oncology

Prognostic Factors in Lenvatinib-Treated Differentiated Thyroid Cancer: A Real-World Study with Extended Follow-Up

2026-11-13T19:45:41.967Z

Cohort study · Eur Thyroid J, 2026.

Artificial Intelligence Models to Predict Recurrence in Patients with Differentiated Thyroid Cancer: A PROBAST + AI Systematic Review of Clinical Applicability

2026-11-13T17:00:16.153Z

Meta-analysis · Thyroid, 2026.

Evaluation of Survival Following Surgical Resection for Small Nonfunctional Pancreatic Neuroendocrine Tumors

2026-11-13T11:00:06.281Z

Cohort study · JAMA Netw Open, 2023. Overall survival, adjusted for preoperative factors (subgroups by tumor size) — Resection, group 1b (1.1-2.0 cm) vs No resection, group 1b: HR for death 0.58 (95% CI 0.42-0.80); P < .001; longer survival with resection

Child and adult adiposity and subtype-specific endometrial cancer risk: a multivariable Mendelian randomisation study

2026-11-13T10:51:50.896Z

Research article · Int J Obes (Lond), 2022. EC risk by subtype (multivariable analyses) — Adult body size: OR 2.30 (95% CI 1.73-3.06); overall EC

Outcomes of lenvatinib therapy in poorly differentiated thyroid carcinoma

2026-11-13T10:09:06.606Z

Cohort study · Eur Thyroid J, 2023. Effectiveness: disease control rate and best response: Disease control rate 100%

The role of procalcitonin in the follow-up of medullary thyroid cancer

2026-11-13T10:09:06.606Z

Cohort study · Eur Thyroid J, 2023. Diagnostic performance of ProCt >0.12 ng/mL for structural disease: ProCt >0.12 ng/mL: AUC 0.963; sensitivity 100%; specificity 83.61%; PPV 74.4%; NPV 100.0%

A Comparison of Outcomes in Medullary Thyroid Carcinoma Patients With and Without a Preoperative Diagnosis: A Multicenter Retrospective Cohort Study

2026-11-13T10:07:06.411Z

Cohort study · Thyroid, 2023. Biochemical cure, last follow-up: no-Dx 55% (CI 0.38-0.71) · preop-Dx 64% (CI 0.50-0.77)

A Comprehensive Study on the Diagnosis and Management of Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features

2026-11-13T10:07:06.411Z

Cohort study · Thyroid, 2023. Clinical, cytological, molecular and imaging features of NIFTP: Female:male ratio 2.7:1

Active Surveillance of Differentiated Thyroid Cancer Metastatic Cervical Lymph Nodes: A Retrospective Single-Center Cohort Study

2026-11-13T10:07:06.411Z

Cohort study · Thyroid, 2023. Disease progression, median AS follow-up 27.5 (IQR, 16.5-47.3) months: AS 14 (35%)

Barriers and Facilitators to the Choice of Active Surveillance for Low-Risk Papillary Thyroid Cancer in China: A Qualitative Study Examining Patient Perspectives

2026-11-13T10:07:06.411Z

Research article · Thyroid, 2023. Barriers and facilitators classified as patient-related, disease-related and external factors

Comparison of Postoperative Unfavorable Events in Patients with Low-Risk Papillary Thyroid Carcinoma: Immediate Surgery Versus Conversion Surgery Following Active Surveillance

2026-11-13T10:07:06.411Z

Cohort study · Thyroid, 2022. Unfavorable events (levothyroxine after surgery, postoperative hematoma, transient/persistent hypoparathyroidism, transient/persistent vocal cord paralysis), CS vs IS: Incidence of unfavorable events did not differ between CS and IS

Disease-Specific Survival Trends for Patients Presenting with Differentiated Thyroid Cancer and Distant Metastases in the United States, 1992–2018

2026-11-13T10:07:06.411Z

Cohort study · Thyroid, 2022. 10-year DSS, DTC with distant metastases, 10 years: 1992-1998 50.2% · 1999-2008 47.3% · 2009-2018 52.4%

Fluctuations in Thyroid Hormone Levels During Initial Treatment for Differentiated Thyroid Carcinoma are Associated with Changes in Hemostasis: A Prospective Cohort Study

2026-11-13T10:07:06.411Z

Cohort study · Thyroid, 2022. THST vs Severe hypothyroidism: CRP, median (IQR) 3.2 (1.3-5.1) vs 1.3 (0.5-3.3) mg/L; p < 0.01; increased during THST

Health-Related Quality of Life and Thyroid Cancer-Specific Symptoms in Patients Treated for Differentiated Thyroid Cancer: A Single-Center Cross-Sectional Survey from Mainland China

2026-11-13T10:07:06.411Z

Cross-sectional study · Thyroid, 2023. HR-QOL: QLQ-C30 global score, mean (SD) 73.12 (11.95)

Hypocalcemia During Lenvatinib Treatment for Advanced Thyroid Cancer: Clinical Features and Management in a Real-Life Setting

2026-11-13T10:07:06.411Z

Cohort study · Thyroid, 2022. Incidence of hypocalcemia: Hypocalcemia occurred in 6 of the 25 patients 24% [95% CI 9.36-45.13%]

Infertility and Pregnancy Rates in Female Thyroid Cancer Survivors: A Retrospective Cohort Study Using Health Care Administrative Data from Israel

2026-11-13T10:07:06.411Z

Cohort study · Thyroid, 2023. TC 23.9%; pregnancy rate 46.9% · Controls 20.4%; pregnancy rate 47.7%

Lenvatinib Compared with Sorafenib as a First-Line Treatment for Radioactive Iodine-Refractory, Progressive, Differentiated Thyroid Carcinoma: Real-World Outcomes in a Multicenter Retrospective Cohort Study

2026-11-13T10:07:06.411Z

Cohort study · Thyroid, 2022. Median PFS: Lenvatinib median 35.3 (CI 18.2 months to upper limit not reported as the median was not reached) months · Sorafenib median 13.3 (CI 9.9-18.1 months) months

Prepregnancy Body Mass Index and Risk of Differentiated Thyroid Cancer: A Prospective Cohort Study of More than 440,000 Danish Women

2026-11-13T10:07:06.411Z

Cohort study · Thyroid, 2022. DTC — Overweight vs Normal weight: HR 1.54 (CI 1.25-1.90)

Prepubertal Children with Papillary Thyroid Carcinoma Present with More Invasive Disease Than Adolescents and Young Adults

2026-11-13T10:07:06.411Z

Cohort study · Thyroid, 2022. Independent predictors of metastases (prepubertal age) — Prepubertal: aOR 1.36 (95% CI 1.01-1.84); p = 0.04; positive regional nodes

Prior Thyroid and Nonthyroid Cancer History Do Not Significantly Alter Overall Survival in Patients Diagnosed with Anaplastic Thyroid Cancer

2026-11-13T10:07:06.411Z

Cohort study · Thyroid, 2023. OS (multivariate analysis adjusted for age and overall stage): Prior DTC, concomitant DTC and prior nonthyroid cancers all had no significant impact on OS

Risk of Adverse Cardiovascular Outcomes in Differentiated Thyroid Cancer Survivors: A Systematic Review and Meta-Analysis

2026-11-13T10:07:06.411Z

Meta-analysis · Thyroid, 2022. CV mortality — DTC survivors vs General population: aRR 3.35 (CI 1.66-6.67); one study adjusted for confounders; 524 DTC, 1572 controls

Surgery After BRAF-Directed Therapy Is Associated with Improved Survival in BRAF V600E Mutant Anaplastic Thyroid Cancer: A Single-Center Retrospective Cohort Study

2026-11-13T10:07:06.411Z

Cohort study · Thyroid, 2023. 12-month OS, 12 months: Neoadjuvant BRAF therapy + surgery 93.6% (CI 84.9-100) · Surgery before BRAF therapy 74.1% (CI 48.7-99.5) · No surgery 38.5% (CI 12.1-64.9)

An Undetectable Postoperative Calcitonin Level Is Associated with Long-Term Disease-Free Survival in Medullary Thyroid Carcinoma: Results of a Retrospective Cohort Study

2026-11-13T10:07:06.411Z

Cohort study · Thyroid, 2022. Disease-free status at last visit, median follow-up 7.7 years (2.1-13.2 years): Undetectable POCal 127 (90.1%) · Detectable POCal 18 (9.2%)

Association of Body Mass Index With Clinicopathological Features of Papillary Thyroid Carcinoma: A Retrospective Study

2026-11-13T10:04:31.875Z

Cohort study · Endocr Pract, 2022. Clinicopathological features of PTC — Overweight vs Normal weight: OR 1.295; P < .05 for all; bilaterality

Comparative Study of Initial Post-Therapeutic 131I Single-Photon Emission Computed Tomography/Computed Tomography and Reoperation for the Detection of Residual Lymph Node Metastasis in Patients With Papillary Thyroid Cancer

2026-11-13T10:04:31.875Z

Diagnostic or prognostic study · Endocr Pract, 2022. Detection of residual LNM: 131I SPECT/CT 95; sensitivity 44.8% (95/212); specificity 91.6% (87/95) · Reoperation 212; patients with LNM confirmed 51 (96.2%)

Persistent or Recurrent Disease in Thyroid Cancer Survivors Who Have Elevated Serum Antithyroglobulin Antibodies

2026-11-13T10:04:31.875Z

Cohort study · Endocr Pract, 2023. Persistent/recurrent disease: Significantly higher incidence of persistent/recurrent disease in TgAb+ vs TgAb-, significant in univariable and multivariable (TgAb status, age, sex) Cox proportional hazards analysis

Age‐dependent changes in the prognostic advantage of papillary thyroid cancer in women: A SEER‐based study

2026-11-13T09:59:57.591Z

Cohort study · Clin Endocrinol (Oxf), 2023. DSS: Women 98.6% · Men 95.4%

Clinical significance of papillary thyroid carcinoma with solid/trabecular growth

2026-11-13T09:59:57.591Z

Cohort study · Clin Endocrinol (Oxf), 2023. PTC-ST vs PTC; p = 0.001; larger tumour size with PTC-ST

Frequency and impact of musculoskeletal symptoms on quality of life in MEN2B

2026-11-13T09:59:57.591Z

Cross-sectional study · Clin Endocrinol (Oxf), 2022. musculoskeletal (MSK) weakness 73% (n = 35)

I‐PET score: Combining whole body iodine and 18F‐FDG PET/CT imaging to predict progression in structurally or biochemically incomplete thyroid cancer

2026-11-13T09:59:57.591Z

Cohort study · Clin Endocrinol (Oxf), 2022. Progression: I-PET [0] 11 (22%) · I-PET [1] 4 (40%) · I-PET [2] 10 (63%) · I-PET [3] 34 (74%)

Limitations of fine‐needle aspiration and core needle biopsies in the diagnosis of tall cell variant of papillary thyroid carcinoma

2026-11-13T09:59:57.591Z

Cohort study · Clin Endocrinol (Oxf), 2022. Most frequent FNA cytomorphological feature in TCV-PTC: tall columnar cells, incl. single tombstone-like cells 70%

Machine learning algorithms are comparable to conventional regression models in predicting distant metastasis of follicular thyroid carcinoma

2026-11-13T09:59:57.591Z

Cohort study · Clin Endocrinol (Oxf), 2022. AUROC for predicting distant metastasis, after 10-fold cross-validation: XGBoost 0.855 (95% CI 0.803-0.906); AUROC 0.855 · LR 0.845 (95% CI 0.818-0.873); AUROC 0.845

The outcome of treatment in differentiated thyroid cancer according to recommendations in current Dutch and American guidelines

2026-11-13T09:59:57.591Z

Cohort study · Clin Endocrinol (Oxf), 2022. Potentially adequate, under- and overtreatment — NL-15 vs ATA-15; p < .001; significantly more over- and adequate treatment with NL-15, more undertreatment with ATA-15 (all)

Ultrasound‐guided thermal ablation for papillary thyroid microcarcinoma: A systematic review

2026-11-13T09:59:57.591Z

Meta-analysis · Clin Endocrinol (Oxf), 2022. Indications, efficacy and safety of TA for PTMC: Indications of TA for PTMC divided into six primary and three secondary indications

Detection of driver mutations in plasma cell–free nucleic acids in differentiated thyroid neoplasm

2026-11-13T09:58:18.729Z

Diagnostic or prognostic study · Eur J Endocrinol, 2023. Driver mutation detected in plasma: Differentiated thyroid cancer 55 (79.71%) · Benign 11

Elevated sphingosine-1-phosphate lyase leads to increased metabolism and reduced survival in adrenocortical carcinoma

2026-11-13T09:58:18.729Z

Mechanistic study · Eur J Endocrinol, 2023. Increased expression of several sphingolipid pathway receptors and enzymes, most notably SGPL1, correlated with reduced patient survival in both cohorts

Target therapy forBRAFmutated anaplastic thyroid cancer: a clinical and molecular study

2026-11-13T09:58:18.729Z

Cohort study · Eur J Endocrinol, 2023. Median overall survival (OS): DT median 475 days · MT median 156 days · CC median 39 days

The management of postoperative disease recurrence in patients with adrenocortical carcinoma: a retrospective study in 106 patients

2026-11-13T09:58:18.729Z

Cohort study · Eur J Endocrinol, 2023. Survival and recurrence pattern, median follow-up 45 months: Group A 35.8% · Group B 20.8% · Group C 43.4%

Radioactive Iodine-Refractory Pulmonary Metastases of Papillary Thyroid Cancer in Children, Adolescents, and Young Adults

2026-11-13T09:55:31.327Z

Cohort study · J Clin Endocrinol Metab, 2022. RAIR disease prevalence: RAIR disease among all patients 30.8% (20/65)

Assessment of Differentiated Thyroid Carcinomas in French Polynesia After Atmospheric Nuclear Tests Performed by France

2026-11-13T05:29:11.680Z

Case-control study · JAMA Netw Open, 2023. Lifetime risk of DTC for the entire FP population (BEIR VII): Excess DTC cases attributable to nuclear tests 29 cases (95% CI, 8-97 cases)

Age-standardized incidence, mortality rate, and trend changes of thyroid cancer in the Balearic Islands during the 2000–2020 period: a population-based study

2026-11-13T04:56:16.556Z

Cohort study · Eur Thyroid J, 2023. ASIR (×105): 2010-2020 6.99 ×105 · 2000-2009 2.82 ×105

Management of hypertension during lenvatinib for advanced thyroid cancer: a suggested diagnostic and therapeutic algorithm

2026-11-13T04:56:16.556Z

Cohort study · Eur Thyroid J, 2023. Incidence of hypertension (HTN) during LEN, mean follow-up 6.8 months: HTN recorded 76% of cases

TSH ≥30 mU/L may not be necessary for successful 131I remnant ablation in patients with differentiated thyroid cancer

2026-11-13T04:56:16.556Z

Cohort study · Eur Thyroid J, 2023. Success rate of RRA — TSH ≥ 30 mU/L vs TSH < 30 mU/L; P = 0.247; no statistical difference

Dysfunction of the Salivary and Lacrimal Glands After Radioiodine Therapy for Thyroid Cancer: Results of the START Study After 6-Months of Follow-Up

2026-11-13T04:54:53.093Z

Cohort study · Thyroid, 2023. Salivary/lacrimal dysfunction, T6 vs T0, 6 months: No difference between T0 and T6 in parotid gland pain level

Head-to-Head Comparison of [ 68 Ga]Ga-DOTA.SA.FAPi and [ 68 Ga]Ga-DOTANOC Positron Emission Tomography/Computed Tomography Imaging for the Follow-Up Surveillance of Patients with Medullary Thyroid Cancer

2026-11-13T04:54:53.093Z

Diagnostic or prognostic study · Thyroid, 2023. [68Ga]Ga-DOTA.SA.FAPi vs [68Ga]Ga-DOTANOC: sensitivity, primary tumors; p = 0.979; 100% [18 of 18] vs 94.4% [17 of 18]

Inequities in Thyroid Cancer Care: Populations Most at Risk for Delays in Diagnosis and Treatment

2026-11-13T04:54:53.093Z

Cohort study · Thyroid, 2023. Delays in care, stage, distant metastases and tumor size by sociodemographic factors: Nonwhite patients who were uninsured or had Medicare or Medicaid were more likely to experience delays in care, present with higher stages at diagnosis, and have distant metastases and larger tumors at presentation

Large (>4 cm) Intrathyroidal Encapsulated Well-Differentiated Follicular Cell-Derived Carcinoma Without Vascular Invasion May Have Negligible Risk of Recurrence Even When Treated with Lobectomy Alone

2026-11-13T04:54:53.093Z

Cohort study · Thyroid, 2023. median follow-up 4.8 years (IQR 3.2-9.7 years): Nodal metastasis at primary resection (all classic-type papillary thyroid carcinoma (PTC)) 5 patients

Long-Term Outcomes of Active Surveillance and Immediate Surgery for Adult Patients with Low-Risk Papillary Thyroid Microcarcinoma: 30-Year Experience

2026-11-13T04:54:53.093Z

Cohort study · Thyroid, 2023. Lymph node metastasis, 10 and 20 years: AS 1.1% at 10 years; 1.7% at 20 years · IS 0.4% at 10 years; 0.7% at 20 years

Molecular Profiles of Noninvasive, Minimally Invasive, and Invasive Follicular Patterned Thyroid Neoplasms with Papillary Nuclear Features

2026-11-13T04:54:53.093Z

Cohort study · Thyroid, 2023. Intermediate and aggressive drivers: NIFTP 0% · EFVPTC 22.3% · iFVPTC 61.6%

Molecular Testing Predicts Incomplete Response to Initial Therapy in Differentiated Thyroid Carcinoma Without Lateral Neck or Distant Metastasis at Presentation: Retrospective Cohort Study

2026-11-13T04:54:53.093Z

Cohort study · Thyroid, 2023. Recurrence by ATA RSS category, 18-month median follow-up: RSS-low 17 (2.9%) · RSS-intermediate 20 (6.7%) · RSS-high 13 (22.8%)